Analytical Data
-
基因名
I-309/CCL1
-
简介
I-309/CCL1 Protein, Mouse (HEK293, Fc) is a cytokine that mediates inflammatory immune responses, viral infections, and tumorigenesis by interacting with the CCR8 chemokine receptor on the cell surface and attracting monocytes, natural killer cells, and immature B-cell nuclear dendritic cells. I-309/CCL1 Protein, Mouse (HEK293, Fc) is a recombinant mouse CCL1 (K24-C92) expressed by HEK293 with a -hFc tag at the nitrogen end[1].
- Application
-
别名
C-C motif chemokine 1; CCL1; SCYA1; TCA-3
-
种属
Mouse
-
表达系统
HEK293
-
标签
N-hFc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P10146
-
表达区间
K24-C92
-
蛋白长度
Full Length of Mature Protein
-
分子量
44 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
I-309, also known as CCL1 (chemokine (C-C motif) ligand 1), is a chemokine that is increasingly recognized for its role in immune response and inflammation. This small protein is primarily involved in the recruitment and activation of lymphocytes, particularly T cells and eosinophils, to sites of inflammation. The study of I-309/CCL1 has gained traction due to its potential implications in various diseases, including asthma, allergies, and autoimmune disorders, where enhanced immune responses contribute to pathology. Research has focused on understanding its signaling mechanisms and biological functions, particularly through its interaction with the CCR8 receptor, which is predominantly expressed on Th2 cells and regulatory T cells. Moreover, the therapeutic potential of targeting the I-309/CCL1 axis has been explored in the context of modulating immune responses, offering avenues for novel treatments in inflammatory and allergic diseases. Recombinant I-309/CCL1 proteins have been utilized in studies to elucidate their role in chemotaxis, cell signaling, and to explore their utility in therapeutic applications such as vaccine development and anti-inflammatory strategies. The ongoing research into this chemokine highlights its significance in the broader context of immunology and its promise as a target for innovative therapeutic interventions.
